PL4305034T3 - Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania - Google Patents

Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania

Info

Publication number
PL4305034T3
PL4305034T3 PL23722475.3T PL23722475T PL4305034T3 PL 4305034 T3 PL4305034 T3 PL 4305034T3 PL 23722475 T PL23722475 T PL 23722475T PL 4305034 T3 PL4305034 T3 PL 4305034T3
Authority
PL
Poland
Prior art keywords
bridged tricyclic
carbamoylpyridone compounds
carbamoylpyridone
compounds
tricyclic
Prior art date
Application number
PL23722475.3T
Other languages
English (en)
Inventor
Hang CHU
Ana Z. GONZALEZ BUENROSTRO
Xiaochun Han
Anna E. Hurtley
Lan Jiang
Jiayao Li
Gregg M. SCHWARZWALDER
Devleena M. SHIVAKUMAR
Matthew J. VON BARGEN
Qiaoyin Wu
Hong Yang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4305034T3 publication Critical patent/PL4305034T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL23722475.3T 2022-04-06 2023-04-05 Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania PL4305034T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328061P 2022-04-06 2022-04-06
US202263476873P 2022-12-22 2022-12-22
PCT/US2023/065401 WO2023196875A1 (en) 2022-04-06 2023-04-05 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Publications (1)

Publication Number Publication Date
PL4305034T3 true PL4305034T3 (pl) 2024-10-14

Family

ID=86330110

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23722475.3T PL4305034T3 (pl) 2022-04-06 2023-04-05 Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania
PL23203855.4T PL4310087T3 (pl) 2022-04-06 2023-04-05 Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23203855.4T PL4310087T3 (pl) 2022-04-06 2023-04-05 Mostkowane, trójcykliczne związki karbamoilopirydonowe i ich zastosowania

Country Status (26)

Country Link
US (3) US12054496B2 (pl)
EP (3) EP4305034B1 (pl)
JP (3) JP7668428B2 (pl)
KR (1) KR20250002321A (pl)
CN (2) CN118922419B (pl)
AU (3) AU2023249631B2 (pl)
CA (1) CA3245817A1 (pl)
CL (3) CL2024002988A1 (pl)
CO (1) CO2024013492A2 (pl)
CR (1) CR20240405A (pl)
DK (2) DK4310087T3 (pl)
DO (1) DOP2024000195A (pl)
ES (2) ES2988416T3 (pl)
FI (2) FI4310087T3 (pl)
HR (2) HRP20241051T1 (pl)
HU (2) HUE067768T2 (pl)
IL (1) IL315684A (pl)
LT (2) LT4310087T (pl)
MX (1) MX2024011695A (pl)
PE (3) PE20252269A1 (pl)
PL (2) PL4305034T3 (pl)
PT (2) PT4305034T (pl)
SI (2) SI4305034T1 (pl)
TW (3) TW202446773A (pl)
WO (1) WO2023196875A1 (pl)
ZA (2) ZA202406990B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111358652B (zh) 2014-10-27 2022-08-16 直观外科手术操作公司 用于集成的手术台运动的系统和方法
KR102628659B1 (ko) 2014-10-27 2024-01-25 인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 반응 운동 동안 제어점을 감시하기 위한 시스템 및 방법
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
WO2025080850A1 (en) * 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) * 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2024357911A1 (en) * 2023-10-11 2026-03-26 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202525289A (zh) * 2023-12-22 2025-07-01 美商基利科學股份有限公司 用於製備治療性化合物之方法及中間物

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
AU2006228278C1 (en) 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Hivインテグラーゼ阻害活性を有する多環性化合物
JP2009503081A (ja) 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Hivインテグラーゼ阻害薬
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
AU2006306355A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
EP1950212B1 (en) 2005-10-27 2016-02-24 Shionogi Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
AU2007313293A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2231621B1 (en) 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
RS54008B1 (sr) 2008-04-23 2015-10-30 Gilead Sciences Inc. 1`-supstituisani karba-nukleozidni analozi za antivirusnu terapiju
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
EP2247601B1 (en) 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones and uses thereof
US8217034B2 (en) 2008-07-25 2012-07-10 Shionogi & Co., Ltd. Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
KR101695807B1 (ko) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 화합물
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CA2738814C (en) 2008-10-06 2014-01-28 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
DK2364314T3 (da) 2008-12-09 2014-05-12 Gilead Sciences Inc Modulatorer af toll-lignende receptorer
EP3210603A1 (en) 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
AU2010208470A1 (en) 2009-01-28 2011-08-04 Merck Sharp & Dohme Corp. Bridged compounds as HIV integrase inhibitors
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2444400B1 (en) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. Toll様レセプターモジュレーターとしての置換ベンゾアゼピン
DK2467380T3 (en) 2009-08-18 2017-03-13 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
WO2011025683A1 (en) 2009-08-26 2011-03-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
LT2932970T (lt) 2010-01-27 2018-06-25 Viiv Healthcare Company Antivirusinė terapija
KR20120130185A (ko) 2010-02-26 2012-11-29 니뽄 다바코 산교 가부시키가이샤 1,3,4,8―테트라히드로―2H―피리도[1,2―a]피라진 유도체 및 그의 HIV 인테그라제 저해제로서의 이용
BR112012024796A2 (pt) 2010-04-02 2016-06-07 Janssen R&D Ireland inibidores de integrase macrocíclicos
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
AR082080A1 (es) 2010-07-02 2012-11-07 Gilead Sciences Inc Compuestos derivados de acido acetico-2-quinolinicos como compuestos antivirales anti hiv
TWI453208B (zh) 2010-07-02 2014-09-21 Gilead Sciences Inc 治療性化合物類
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
PL3456721T3 (pl) 2010-08-05 2021-10-25 Shionogi & Co., Ltd Sposób wytwarzania związków wykazujących działanie hamujące integrazę hiv
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
BR112013007678A2 (pt) 2010-10-01 2017-07-04 Ventirx Pharmaceuticals Inc método para tratamento de doenças alérgicas
EP3195868A3 (en) 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
AU2011320651A1 (en) 2010-10-29 2013-05-02 Merck Canada Inc. HIV integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
CN106518851A (zh) 2011-01-12 2017-03-22 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN106749023A (zh) 2011-01-12 2017-05-31 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
PT2699558T (pt) 2011-04-21 2016-12-29 Gilead Sciences Inc Compostos de benzotiazole e a sua utilização farmacêutica
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
EA201990685A1 (ru) 2011-05-17 2019-12-30 Дзе Рокфеллер Юниверсити Нейтрализующие вирус иммунодефицита человека антитела и способы их применения
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
WO2013025788A1 (en) 2011-08-16 2013-02-21 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
JP6144698B2 (ja) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hiv複製の阻害剤としての縮合三環式化合物
TWI580668B (zh) 2011-12-21 2017-05-01 諾維拉治療公司 B型肝炎抗病毒劑
EP2812331B1 (en) 2012-02-08 2019-01-02 Janssen Sciences Ireland Unlimited Company Piperidino-pyrimidine derivatives for the treatment of viral infections
US20150044137A1 (en) 2012-03-23 2015-02-12 The United States of America, as represented by the Secretary, Dep. of Health Care Human Services Neutralizing antibodies to hiv-1 and their use
PT3070081T (pt) 2012-04-20 2018-05-21 Gilead Sciences Inc Derivados do ácido benzotiazol-6-ilacético e sua utilização para tratar uma infeção por vih
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
WO2014014933A1 (en) 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
CN104781239B (zh) 2012-08-10 2019-03-01 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
SI3333173T1 (sl) 2012-10-03 2019-08-30 Gilead Sciences, Inc. Postopki za pripravo analogov protivirusnega nukleotida
EP2906563B1 (en) 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SI2908912T1 (sl) 2012-10-18 2021-03-31 The Rockefeller University Široko nevtralizirajoča protitelesa proti HIV
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP2928924A4 (en) 2012-12-04 2016-07-13 Univ Maryland HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
AU2013366981A1 (en) 2012-12-27 2015-06-18 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
EP3330272B1 (en) 2013-05-17 2021-02-17 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
NO2865735T3 (pl) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20160244510A1 (en) 2013-09-27 2016-08-25 Duke University Human monoclonal antibodies
KR102102516B1 (ko) 2013-09-27 2020-04-20 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 치환된 퀴놀리진 유도체
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
NO2717902T3 (pl) * 2014-06-20 2018-06-23
US10676521B2 (en) 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers
EP3757105B1 (en) 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
BR112017003663A2 (pt) 2014-08-27 2017-11-28 Viiv Healthcare Uk No 5 Ltd composto, composição, e, método para tratamento de infecção por hiv.
EP3229804B1 (en) 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
HRP20200583T1 (hr) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
WO2016154527A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3377065B1 (en) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017096221A1 (en) 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
US20200079862A1 (en) 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
HUE056243T2 (hu) 2015-12-15 2022-02-28 Gilead Sciences Inc Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN107022027B (zh) 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
DK3347352T3 (da) 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3548031B1 (en) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP3752144B1 (en) 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JP2021522254A (ja) 2018-04-27 2021-08-30 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
EP3802543A1 (en) 2018-05-31 2021-04-14 F. Hoffmann-La Roche AG Therapeutic compounds
PE20251594A1 (es) 2018-05-31 2025-06-16 Shionogi & Co Derivado policiclico de carbamoilpiridona
AU2019277547B2 (en) 2018-05-31 2024-10-10 Shionogi & Co., Ltd. Polycyclic pyridone derivative
US11884683B2 (en) 2018-06-05 2024-01-30 Merck Sharp & Dohme Llc Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
KR102579246B1 (ko) 2018-07-03 2023-09-19 길리애드 사이언시즈, 인코포레이티드 HIV gp120을 표적화하는 항체 및 사용 방법
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
IL282551B2 (en) 2018-10-22 2025-11-01 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
CN113795491B (zh) 2019-04-30 2024-09-03 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
WO2021093846A1 (zh) 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 新型四环杂环化合物及其药物用途
JPWO2021107066A1 (pl) 2019-11-28 2021-06-03
US12577241B2 (en) 2019-11-28 2026-03-17 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202227445A (zh) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的hiv病毒的用途
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
KR20230147131A (ko) 2021-02-16 2023-10-20 머크 샤프 앤드 돔 엘엘씨 Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물

Also Published As

Publication number Publication date
EP4310087B1 (en) 2024-07-03
MX2024011695A (es) 2024-11-08
DK4310087T3 (da) 2024-07-15
US12024528B2 (en) 2024-07-02
CN118922419A (zh) 2024-11-08
TW202446773A (zh) 2024-12-01
JP2025071130A (ja) 2025-05-02
DK4305034T3 (da) 2024-07-01
HUE067983T2 (hu) 2024-12-28
EP4438123A3 (en) 2024-12-04
TW202400165A (zh) 2024-01-01
IL315684A (en) 2024-11-01
HRP20240986T1 (hr) 2024-11-08
FI4310087T3 (fi) 2024-08-09
US12054496B2 (en) 2024-08-06
EP4305034A1 (en) 2024-01-17
HRP20241051T1 (hr) 2024-11-08
AU2025205450A1 (en) 2025-07-31
US20230339971A1 (en) 2023-10-26
ES2988416T3 (es) 2024-11-20
JP2025510905A (ja) 2025-04-15
JP7668428B2 (ja) 2025-04-24
CR20240405A (es) 2024-11-28
AU2023249631A1 (en) 2024-10-03
CL2025002304A1 (es) 2025-11-21
EP4310087A1 (en) 2024-01-24
HUE067768T2 (hu) 2024-11-28
TWI856796B (zh) 2024-09-21
CL2025002302A1 (es) 2025-11-21
US20250115620A1 (en) 2025-04-10
PL4310087T3 (pl) 2024-11-04
FI4305034T3 (fi) 2024-07-25
LT4310087T (lt) 2024-08-26
PT4305034T (pt) 2024-06-25
AU2025201145B2 (en) 2025-03-13
EP4305034B1 (en) 2024-06-12
CN120081853A (zh) 2025-06-03
AU2025201145A1 (en) 2025-03-06
PE20252269A1 (es) 2025-09-15
PT4310087T (pt) 2024-08-02
CO2024013492A2 (es) 2024-10-31
SI4305034T1 (sl) 2024-08-30
NZ818531A (en) 2025-06-27
ES2992835T3 (en) 2024-12-18
CN118922419B (zh) 2025-11-28
KR20250002321A (ko) 2025-01-07
TWI843506B (zh) 2024-05-21
JP7668430B1 (ja) 2025-04-24
WO2023196875A1 (en) 2023-10-12
PE20252272A1 (es) 2025-09-15
NZ814609A (en) 2025-05-02
JP2025081461A (ja) 2025-05-27
TW202400172A (zh) 2024-01-01
US20230339972A1 (en) 2023-10-26
PE20250151A1 (es) 2025-01-16
ZA202406990B (en) 2025-04-30
CL2024002988A1 (es) 2025-02-21
CA3245817A1 (en) 2023-10-12
DOP2024000195A (es) 2025-03-31
LT4305034T (lt) 2024-07-10
ZA202501263B (en) 2025-10-29
AU2023249631B2 (en) 2025-04-24
EP4438123A2 (en) 2024-10-02
SI4310087T1 (sl) 2024-09-30

Similar Documents

Publication Publication Date Title
HUE067768T2 (hu) Áthidalt triciklusos karbamoilpiridon-vegyületek és alkalmazásaik
IL319660A (en) Tricyclic compounds and their uses
SG11202109650XA (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
IL304700A (en) Tetracyclic Oxazapine Compounds and Their Uses
IL316531A (en) Compounds and their uses
IL289416B (en) A tricyclic compound and its use
IL288672B2 (en) Tricyclic compounds and their use
EP3956331A4 (en) BICYCLIC AND TRICYCLIC COMPOUNDS
ZA202303688B (en) Substituted tricyclic compounds
EP4495115A4 (en) TETRACYCLIC COMPOUND AND USE THEREOF
IL304819A (en) Tricyclic compounds and their uses
IL317807A (en) Polymorphic compounds and their uses
HK40092944B (zh) 桥连三环氨基甲酰基吡啶酮化合物及其用途
CA3304384A1 (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
AU2024360779A1 (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
CA3304209A1 (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
CA3305354A1 (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
HK40097220A (en) Bridged tricyclic carbamoylpyridone compounds and uses thereof
GB202307065D0 (en) Novel compounds and uses thereof
HK40118684A (en) Tricyclic compounds and uses thereof
IL320688A (en) Tricyclic compounds
HK40122692A (zh) 三环化合物及其用途
CA3270086A1 (en) Tricyclic compounds and their uses
GB202208260D0 (en) Novel compounds and their uses
GB202208257D0 (en) Novel compounds and their uses